{"id":"bb788f1a-3d64-4bea-9dc2-b3f01335a3c1","arxiv_id":"2508.10284","paper_version":1,"verdict":"UNVERDICTED","confidence":"LOW","novelty_score":4.0,"correctness_risk":"unknown","formal_verification":"none","parameter_count":2,"one_line_summary":"A two-stage conformal model predicts whether Parkinson's patients need medication changes and bounds future levodopa-equivalent dose adjustments with calibrated intervals.","lead":"A preprint abstract proposes a two-stage conformal prediction model that anticipates Parkinson's disease medication dose changes up to two years ahead, with prediction intervals and coverage guarantees. The text provided as the full paper is actually a different article about efficient reasoning models, so this report can only evaluate the abstract, not the claimed results.","discovery_kind":"new_application","skeptic_critique":{"model":"deepseek-v4-flash","headline":"The submitted body text is an unrelated paper on verifiable stepwise rewards, so the PD conformal-prediction methods and empirical coverage results are absent; the central claim is unverifiable from the artifact.","rationale":"The reader's verdict was UNVERDICTED with LOW confidence, and the reader's rationale correctly noted that the artifact's body text is an unrelated cs.AI paper. However, the reader's stated weakest_assumption was the exchangeability/clinical transferability of the 631 inpatient admissions. That is a legitimate substantive assumption, but it presumes that the methods and results are present and testable. The most immediate load-bearing problem is more basic: the submitted text contains no methods, no experiments, and no results for the PD conformal-prediction system, so the abstract's empirical assertions cannot be checked at all. The exchangeability concern would become the dominant issue only if a complete PD manuscript were supplied. Because the reader already arrived at UNVERDICTED, this concern does not change the verdict; it reinforces it. I therefore recommend UNCHANGED, with the understanding that the fundamental blocker is the missing body text rather than the exchangeability assumption alone.","tokens_in":2468,"tokens_out":2640,"duration_ms":31506,"concrete_test":"Retrieve the complete PD paper from arXiv:2508.10284 (e.g., v1 or a linked repository). If the body still consists of the VSRM paper, the concern is confirmed and the abstract's coverage claim cannot be checked. If the full PD text is obtained, locate the conformal calibration section and attempt to reproduce the reported marginal coverage on a held-out exchangeable split of the 631 admissions using the specified two-stage nonconformity score; verify that coverage is within Monte Carlo error of the target 1-alpha and that interval-length reductions are computed at matched coverage. Absence of the calibration procedure or evaluation code would leave the central claim unverifiable.","verdict_should_be":"UNCHANGED","load_bearing_attack":"The central claim is that a two-stage conformal predictor, trained on 631 inpatient admissions, achieves marginal coverage while producing shorter prediction intervals for levodopa-equivalent daily dose adjustments up to two years ahead. For this claim to be assessable, the artifact must contain at least: the split-conformal construction, the two-stage nonconformity score (change/no-change stage and conditional dose-quantile stage), the calibration/evaluation protocol, and the empirical coverage and interval-length results. Instead, the full text is 'Promoting Efficient Reasoning with Verifiable Stepwise Reward' (arXiv:2508.10293), containing no PD data, no conformal methodology, and no coverage tables. This is an internal mismatch in the submitted artifact, not a disagreement with consensus. The reader's identified exchangeability/clinical-transfer assumption is secondary: even if the 631 admissions were perfectly exchangeable with the outpatient target population, the in-scope text provides no way to check whether the two-stage procedure actually attains marginal coverage or whether shorter intervals are not simply an artifact of under-coverage. The missing evidence is therefore the most load-bearing concern.","agreement_with_reader":"partial"},"referee_report":{"model":"deepseek-v4-flash","summary":"The abstract describes a two-stage conformal prediction framework for forecasting Parkinson's disease medication needs (levodopa-equivalent daily dose adjustments) up to two years ahead, using electronic health records from 631 inpatient admissions at University of Florida Health (2011-2021). The abstract claims that the framework achieves marginal coverage while yielding shorter prediction intervals than traditional approaches. However, the submitted full text is an unrelated manuscript, 'Promoting Efficient Reasoning with Verifiable Stepwise Reward' (arXiv:2508.10293), which discusses reinforcement learning for large reasoning models. None of the methods, experiments, or results described in the abstract appear in the body of the submitted artifact.","tokens_in":2729,"tokens_out":1553,"duration_ms":18839,"significance":"If substantiated, the proposed two-stage conformal approach could be a meaningful contribution to clinical decision support for Parkinson's disease, particularly in addressing zero-inflated medication data and providing uncertainty-aware predictions with finite-sample coverage guarantees. However, the submitted manuscript does not provide any of the evidence needed to assess this contribution: there is no split-conformal construction, no nonconformity score, no calibration protocol, no empirical coverage or interval-length tables, and no dataset analysis. The potential significance is therefore entirely speculative on the basis of this submission.","major_comments":[{"comment":"The submitted full text is a different paper on verifiable stepwise rewards for large reasoning models; it contains no Parkinson's disease data, no conformal prediction methodology, and no prediction-interval results. The central claim in the abstract—that the two-stage framework achieved marginal coverage with shorter intervals—is therefore entirely unsupported by the artifact. This is an internal mismatch that prevents any verification of the paper's core contribution.","section":"Full text (all sections)"},{"comment":"The abstract states that the framework 'achieved marginal coverage' but does not specify the conformal miscoverage level alpha, the calibration set size or split, the nonconformity score for the two stages (change/no-change and conditional dose-quantile), or the empirical coverage rate. Without these, the marginal coverage claim is not assessable. The reader's stress-test note correctly identifies this missing evidence as the most load-bearing concern.","section":"Abstract"},{"comment":"The claim of 'reducing prediction interval lengths compared to traditional approaches' is stated without defining the comparator (e.g., which traditional conformal baseline), the evaluation metric (e.g., mean interval width, median width), or error bars/confidence intervals for the comparison. Shorter intervals are only meaningful if coverage is simultaneously verified; the manuscript provides no way to rule out that shorter intervals result from under-coverage.","section":"Abstract"},{"comment":"The training sample of 631 inpatient admissions from one health system (2011-2021) is used to predict medication needs up to two years ahead, presumably for an outpatient population. The abstract offers no discussion of temporal drift, patient overlap, or exchangeability between the calibration/ training distribution and the target deployment distribution. Even if the two-stage method were fully described, the marginal coverage guarantee would rest on this sampling assumption, which is neither stated nor defended.","section":"Abstract"}],"minor_comments":[{"comment":"The abstract uses the term 'marginal coverage' without formally defining the probability statement. Standard conformal literature defines it as 1 - alpha coverage over a new exchangeable sample; the manuscript should state this explicitly.","section":"Abstract"},{"comment":"The phrase 'precise predictions for short-term planning and wider ranges for long-term forecasting' is vague. If this is an empirical finding, it should be tied to a specific horizon-dependent analysis in the results.","section":"Abstract"},{"comment":"The unrelated full text contains a figure caption (Figure 5) and other content that are not part of the Parkinson's disease study. If this is a submission error, the correct manuscript should be uploaded; as is, the artifact is internally inconsistent.","section":"Full text"}],"recommendation":"reject","confidential_remarks":"The submitted full text is a completely different paper from the one described in the abstract. This is not a matter of disagreement with the authors' conclusions; the artifact does not contain the claimed study at all. Unless this is a submission error that can be corrected before review, the paper cannot be meaningfully evaluated. The editor may wish to verify that the correct PDF was uploaded."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"The abstract is genuinely promising: Parkinson's medication dosing is a real clinical pain point, the two-stage idea (first detect who will change, then predict the dose adjustment) is a sensible way to handle zero-inflation, and conformal prediction is the right tool for calibrated intervals. If the actual manuscript matches the abstract, this could be a solid decision-support paper.\n\nBut the full text we received is not that paper. It is a cs.AI paper on stepwise rewards for large reasoning models. No conformal construction, no nonconformity score, no calibration protocol, no coverage tables, no code, no data. The abstract's central claim—marginal coverage with shorter intervals—is therefore unverifiable. We cannot even check whether the shorter intervals are simply an artifact of under-coverage. The stress-test note gets this exactly right: the missing evidence is the load-bearing concern, not the exchangeability of the 631 inpatient admissions. That sampling issue matters, but it is secondary when we cannot see any of the actual method.\n\nWhat credit is due? The abstract is well-written and the authors clearly understand the clinical setting and the conformal framework. The zero-inflation motivation is reasonable, and the two-stage structure is a plausible response. None of that is enough to evaluate the work, because none of the supporting detail exists in the artifact.\n\nAs submitted, this should not go to peer review. A referee would have nothing to read. The right move is to return it to the authors for the correct full text. If the real manuscript arrives, it deserves a serious look: the problem is important, the approach is sensible, and the bar for a useful result is clear (calibrated coverage plus genuinely shorter intervals). Until then, there is no paper to evaluate.\n\nI would not cite this or bring it to reading group on the basis of the abstract alone. The artifact is internally inconsistent, so I cannot call it a coherent piece of work.","headline":"The abstract describes a sensible clinical conformal prediction study, but the submitted full text is an unrelated cs.AI paper, so the methods and coverage results are absent; the artifact as submitted cannot be evaluated.","tokens_in":3158,"tokens_out":1817,"would_cite":false,"duration_ms":20831,"reading_group":"no","serious_thinker":"no","would_accept_peer_review":false},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"deepseek-v4-flash","headline":"Two-stage conformal prediction on 631 inpatient records yields statistically valid, clinically usable prediction intervals for Parkinson's medication dose changes up to two years ahead.","keywords":["conformal prediction","Parkinson's disease","levodopa equivalent daily dose","uncertainty quantification","electronic health records","two-stage prediction","zero-inflated data"],"falsifier":"Take the trained two-stage model and run it on a separate cohort of Parkinson's patients from a different hospital or a later time period; compute the empirical coverage of the reported prediction intervals. If the empirical coverage falls materially below the advertised marginal coverage (e.g., below 80% for a 90% nominal interval), the exchangeability assumption is violated and the paper's main statistical claim fails. A more specific version: if a no-change classifier has the same AUC as random guessing, the two-stage design does not improve on a single conformal regressor.","tokens_in":2386,"feed_emoji":"💊","tokens_out":5801,"duration_ms":54406,"temperature":0.7,"pith_summary":"The paper aims to show that uncertainty-aware prediction of Parkinson's disease medication needs is feasible with a two-stage conformal prediction framework. Using electronic health records from 631 inpatient admissions, the framework first identifies patients likely to require a dose change and then predicts the size of the adjustment, expressed as levodopa-equivalent daily dose, with a prediction interval. The authors report that the intervals achieve marginal coverage while being shorter than those from traditional approaches, so that short-term forecasts are precise and long-term forecasts honestly widen. If the claim holds, clinicians could replace trial-and-error dosing with interval-based guidance that carries a statistical guarantee.","feed_headline":"Valid dose-forecast bands for Parkinson's, via conformal method","feed_subtitle":"A two-stage model on EHR data keeps short-term intervals tight and long-term ranges wide with marginal coverage.","key_machinery":"The central mechanism is a two-stage conformal prediction pipeline. Stage one is a classification model that separates stable patients (no dose change) from those who will undergo a change, so the zero-inflated target is modeled explicitly. Stage two is a conformalized regression model that outputs a prediction interval for the dose adjustment. Conformal prediction provides finite-sample marginal coverage guarantees under exchangeability, which is the statistical property being claimed. The two-stage structure is what lets the framework both flag changes and quantify the magnitude of those changes with calibrated uncertainty.","core_discovery":"The paper's central claim is that a two-stage conformal prediction framework, applied to electronic health records from 631 inpatient admissions over 2011–2021, can produce statistically valid prediction intervals for whether and by how much a Parkinson's patient's levodopa-equivalent daily dose (LEDD) will change, up to two years ahead. The first stage identifies patients likely to need a medication change, addressing the zero-inflated nature of the data; the second stage predicts the size of the dose adjustment with conformal intervals. The authors report that the framework achieves marginal coverage while yielding shorter prediction intervals than traditional approaches, meaning short-ter","pith_inferences":["The paper does not demonstrate that 631 inpatient admissions generalize to outpatient PD trajectories; a held-out outpatient cohort would test whether the conformal coverage guarantee survives the setting shift.","Marginal coverage is an average, not a per-patient promise; conditional calibration across age, disease stage, or baseline LEDD would be needed before a clinician can rely on the interval for an individual.","Because the abstract does not name the 'traditional approaches', the reported interval-length reduction could reflect the base model rather than the two-stage design; comparing against a single conformal regressor on the same data would isolate the contribution.","The two-stage structure could be reused for any zero-inflated clinical endpoint (e.g., hospitalization or relapse), but the width of the second-stage interval will depend on the calibration of the first-stage classifier's change probabilities."],"forward_implications":["If the claim is right, neurologists can receive an interval, not a single number, for a patient's future LEDD, with a stated confidence level.","Short-horizon intervals will be tight enough to support dose titration decisions, potentially reducing trial-and-error and premature escalation.","Long-horizon intervals will be wider, giving clinicians an honest picture of forecast uncertainty and prompting earlier, more cautious monitoring.","The two-stage design could be reused for other chronic conditions where the outcome is zero-inflated (e.g., hospitalization or relapse), because the first stage handles 'no event' explicitly.","The reported reduction in interval length over traditional conformal methods, if it holds on external data, would make uncertainty-aware predictions more clinically useful by reducing ambiguity."],"supporting_citations":[],"fun_headline_variants":["Conformal bands for Parkinson's dose changes, two years out","Parkinson's meds: valid intervals for dose adjustments","Two-stage model forecasts levodopa needs with tight intervals","Statistical guarantees for Parkinson's dosing predictions","Shorter intervals, reliable coverage for PD dose forecasts"],"cache_read_input_tokens":2816,"weakest_assumption_plain":"The whole coverage guarantee rests on the assumption that the 631 inpatient admissions from one health system between 2011 and 2021 are exchangeable with the outpatient Parkinson's patients whose future doses are being forecast, with no drift over time or across care settings.","fun_headline_variants_meta":{"raw":{"variants":["Conformal bands for Parkinson's dose changes, two years out","Parkinson's meds: valid intervals for dose adjustments","Two-stage model forecasts levodopa needs with tight intervals","Statistical guarantees for Parkinson's dosing predictions","Shorter intervals, reliable coverage for PD dose forecasts"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.000409,"raw_usage":{"total_tokens":1983,"prompt_tokens":794,"completion_tokens":1189,"prompt_tokens_details":{"cached_tokens":256},"prompt_cache_hit_tokens":256,"prompt_cache_miss_tokens":538,"completion_tokens_details":{"reasoning_tokens":1112}},"tokens_in":538,"tokens_out":1189,"duration_ms":9224,"temperature":1.0,"reasoning_tokens":1112,"cache_read_input_tokens":256,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-05T20:32:13.498029+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"Take the trained two-stage model and run it on a separate cohort of Parkinson's patients from a different hospital or a later time period; compute the empirical coverage of the reported prediction intervals. If the empirical coverage falls materially below the advertised marginal coverage (e.g., below 80% for a 90% nominal interval), the exchangeability assumption is violated and the paper's main statistical claim fails. A more specific version: if a no-change classifier has the same AUC as random guessing, the two-stage design does not improve on a single conformal regressor.","supporting_citations":[],"review_version":1}